What is the 13F Pro Quality Score for CDRE?

13F Pro ranks Cadre Holdings, Inc. (CDRE) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View CDRE's current score at https://13fpro.ai/research/CDRE (free sign-up required for the full ranking).

Which hedge funds own the most CDRE stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of CDRE include FMR, Greenhouse Funds LLLP, BlackRock,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/CDRE as soon as new 13F filings post.

Where does 13F Pro source CDRE data?

All Cadre Holdings, Inc. fundamentals and ownership data come directly from SEC EDGAR. Cadre Holdings, Inc. files with the SEC under CIK 1860543. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is CDRE in?

Cadre Holdings, Inc. (CDRE) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is CDRE research updated on 13F Pro?

CDRE's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Cadre Holdings, Inc.(CDRE)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →NYSE

Institutional-grade research for retail investors

SEC EDGAR: CIK 1860543 CDRE stock profile & AI dashboard →

13F Pro Quality Score

54.5/100

Rank #1,215 of 2,879 stocksTOP 50%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

65.1/100

Profitability

53.9/100

Balance Sheet

67.3/100

Earnings Quality

35.7/100

Free Cash Flow

63.0/100

Institutional Flow

27.1/100

Revenue Scale

39.7/100

Dilution Risk

41.4/100

CDRE Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Cadre Holdings, Inc. (CDRE), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores CDRE at 54.5/100 on a 32-signal composite quality model, placing it at rank #1,215 of 2,879 stocks — the top half of the AI-ranked universe. Areas of concern include institutional flow (27.1) and earnings quality (35.7), which score below median versus the broader universe. Shareholder dilution risk is elevated at 41.4/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Cadre Holdings, Inc. reports quarterly revenue of $155.4M, net income of $2.0M, free cash flow of $19.8M. Top institutional holders of CDRE by reported 13-F value include FMR, Greenhouse Funds LLLP, BlackRock,, based on the most recent SEC filings. CDRE trades on the NYSE exchange and files with the SEC under CIK 1860543. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CDRE daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Cadre Holdings, Inc. directly from SEC EDGAR. Cadre Holdings, Inc.'s 13F Pro composite quality score has ranged between 32 and 63 since 2022, currently 54.5 — an improving long-term trajectory across 21 quarterly and live scoring snapshots.

✦

Fun facts about Cadre Holdings, Inc.

Quirks, history, and lore behind CDRE — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. defense and public-safety equipment company · small-cap · listed on the NYSE · headquartered in Florida.
2
The Numbers
Annual revenue in the range of $500–600 million, with a business built almost entirely on selling protective gear and duty equipment to government and law-enforcement customers.
3
The History
The company was taken public relatively recently — IPO in 2021 — but its roots go back decades through a string of acquisitions of specialized safety brands.
4
The Secret
Despite being classified under healthcare, its real customers are police officers, corrections officers, and military personnel — people who need armor, not aspirin.
5
The Lore
The company serves as a one-stop shop for duty gear, supplying everything from body armor and ballistic helmets to handcuffs and holsters under a portfolio of acquired brands.
6
The Giveaway
Its very name hints at its mission — a cadre of products protecting those who protect us — and its ticker, CDRE, trades on the NYSE out of Jacksonville.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$155.4M

Net Income

Q1 2026

$2.0M

Free Cash Flow

Q1 2026

$19.8M

D/E Ratio

Q1 2026

1.14

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+26.5% YoY

$610.3MFY 2025

FY20 $404.6MFY22 $457.8MFY23 $482.5MFY25 $610.3M

Net Income

+14.2% YoY

$44.1MFY 2025

FY20 $38.5MFY22 $5.8MFY23 $38.6MFY25 $44.1M

Operating Income

+19.2% YoY

$67.4MFY 2025

FY20 $49.8MFY22 $16.7MFY23 $56.5MFY25 $67.4M

EPS (Diluted)

+0.0% YoY

$1.02FY 2025

FY20 $0.03FY22 $0.16FY23 $1.02FY25 $1.02

Total Assets

+78.6% YoY

$770.0MFY 2025

FY20 $283.3MFY22 $392.0MFY23 $431.2MFY25 $770.0M

Total Debt

+109.2% YoY

$323.5MFY 2025

FY20 $216.3MFY22 $174.1MFY23 $154.6MFY25 $323.5M

Op. Cash Flow

-13.0% YoY

$63.7MFY 2025

FY20 $45.4MFY22 $46.4MFY23 $73.2MFY25 $63.7M

Metric	FY 2025	FY 2023	FY 2022	FY 2020	FY 2019
Revenue	$610.3M +26.5%	$482.5M +5.4%	$457.8M +13.1%	$404.6M	—
Net Income	$44.1M +14.2%	$38.6M +563.9%	$5.8M -84.9%	$38.5M	—
Operating Income	$67.4M +19.2%	$56.5M +238.1%	$16.7M -66.4%	$49.8M	—
EPS (Diluted)	$1.02 +0.0%	$1.02 +537.5%	$0.16 +471.4%	$0.03	—
Total Assets	$770.0M +78.6%	$431.2M +10.0%	$392.0M +38.4%	$283.3M	—
Total Debt	$323.5M +109.2%	$154.6M -11.2%	$174.1M -19.5%	$216.3M	—
Operating Cash Flow	$63.7M -13.0%	$73.2M +57.7%	$46.4M +2.2%	$45.4M	—

AI Insight: CDRE Financial Trends

Q1 2026 net income collapsed to $2M — lowest in eight quarters — while total debt surged to $382M, a 65% jump from Q1 2025.

• Revenue grew year-over-year from $130M in Q1 2025 to $155M in Q1 2026, a 19% increase.

• Operating income dropped sharply to $7M in Q1 2026 from $14M in Q1 2025, implying significant margin compression.

• Total debt jumped from $232M in Q1 2025 to $382M in Q1 2026, a $150M increase in four quarters.

• Operating cash flow improved to $23M in Q1 2026 versus $17M in Q1 2025, a rare bright spot.

⚠ Net income of $2M in Q1 2026 is the weakest in the dataset — watch whether cost pressures are structural or transitory.

⚠ Equity dipped to $318M in Q4 2025 before recovering to $336M in Q1 2026; debt-to-equity now stands at 1.14x.

⚠ Operating CF of $23M despite weak net income suggests non-cash charges — monitor what is driving the earnings gap.

AI Insight: CDRE Ratio Trends

Q1 2026 marks a sharp profitability collapse, with operating margin hitting 4.8% and ROIC falling to 4.2% — the weakest readings in the dataset.

• Operating margin plunged from 12.2% in Q4 2025 to 4.8% in Q1 2026, the lowest single-quarter level recorded.

• Net profit margin collapsed to 1.3% in Q1 2026, down from 7.0% in Q4 2025 and 7.8% in Q2 2025.

• D/E ratio has risen steadily from 0.73 in Q1 2025 to 1.14 in Q1 2026, signaling increasing leverage.

• ROIC dropped to 4.2% in Q1 2026 from 12.8% in Q4 2025, erasing gains built over the prior three quarters.

⚠ Q1 has historically been weak (Q1 2025 OpMargin: 10.4% vs Q4 2024: 16.7%) — monitor whether Q1 2026's severity is seasonal or structural.

⚠ D/E at 1.14 is the highest in the dataset; rising leverage alongside falling returns warrants close balance-sheet scrutiny.

⚠ TTM OpMargin of 9.6% trails most individual quarters, suggesting recent weakness is dragging the full-year trend lower.

Get alerted when CDRE's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Cadre Holdings, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of CDRE

FMR LLC
$101.8M3,319,196 sh
Greenhouse Funds LLLP
$88.0M2,868,378 sh
BlackRock, Inc.
$80.6M2,626,383 sh
REINHART PARTNERS, LLC.
$68.7M2,237,897 sh
STATE STREET CORP
$42.8M1,396,323 sh
Capital International Investors
$38.7M1,260,806 sh
VANGUARD CAPITAL MANAGEMENT LLC
$38.3M1,247,449 sh
Capital World Investors
$36.0M1,172,357 sh
WYNNEFIELD CAPITAL INC
$35.3M1,150,000 sh
BROWN ADVISORY INC
$26.3M855,954 sh

Fund	Value	Shares
FMR LLC	$101.8M	3,319,196
Greenhouse Funds LLLP	$88.0M	2,868,378
BlackRock, Inc.	$80.6M	2,626,383
REINHART PARTNERS, LLC.	$68.7M	2,237,897
STATE STREET CORP	$42.8M	1,396,323
Capital International Investors	$38.7M	1,260,806
VANGUARD CAPITAL MANAGEMENT LLC	$38.3M	1,247,449
Capital World Investors	$36.0M	1,172,357
WYNNEFIELD CAPITAL INC	$35.3M	1,150,000
BROWN ADVISORY INC	$26.3M	855,954

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put CDRE on your watchlist

Track score changes the day Cadre Holdings, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is CDRE a good stock to buy?

13F Pro's AI-powered analysis of Cadre Holdings, Inc. (CDRE) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CDRE are available on the CDRE stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own CDRE?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CDRE. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Cadre Holdings, Inc.'s investment landscape.